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swab) nucleotide difference in VP1 compared with the Sabin
strain. These results conﬁrm the presence of an iVDPV1. The
sequences of 5ˇıNCR showed the 480 nucleotide change, prov-
ing the reversion of the sabin strain to the infectivity. These
ﬁndings were sent to the National Program in less than 15
days.
Results: After the detection of AFP notiﬁcation was sent
to the ﬁeld, Epidemiology actions were made as in all cases.
In the investigation three different locations were estab-
lished as the child residence. All of them were visited and
vaccination of all children under 18 years old was done. A
national and international alert were sent Active community
surveillance was made and contact and environmental sam-
ples were collected and sent to the Regional Lab. In none
of them the iVDPV 1 was detected. Four serial samples from
the case were taken each month, in all of them the same
iVDPV1 was isolated.
Conclusion: The country has sustained the surveillance
of AFP through 22 years based on the collaborative work
between the laboratory and the epidemiologists. No other
cases appeared although the vaccine coverage in one of
the district was very low. As consequence of this ﬁnd-
ing a national vaccination campaign was made. Although
poliomyelitis is a threat to the region Argentine is ready to
face it.
doi:10.1016/j.ijid.2010.02.628
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Background: The acronym ESAVI deﬁnes any clinical pic-
ture after vaccination chronologically related to its use.
Further analysis of the event determines the role of the
vaccine in its causality. In the case of YFV, three cate-
gories of severe adverse events are described: anaphylactic
reactions, YF neurotropic disease (YFV-AND), viscerotropic
disease (YFV-AVD). YFV is included in Argentinaˇıs national
immunization program for use in population older than
one year of age in regions with transmission risk. It is
also prescribed to travelers to endemic zones and can be
required upon International Health Regulation allowance.
We describe the clinical, epidemiological and laboratory
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roﬁle of ESAVIs in the context of an extraordinarily
ncreased YFV administration in Argentina in 2008, due to
eported fatal cases involving humans and monkeys in risk
ones.
Methods: This is a descriptive study encompassing the
eriod between January and December, 2008. Complete
FV-ESAVI forms were included, after the expert commit-
ee evaluations. Adverse events were grouped using current
AHO/WHO classiﬁcation. Samples (serum, CSF and liver
iopsies) were processed at the INEVH through standard
echniques.
Vaccine shots: 1,806,400.
Results: Fifty ESAVIs were included:
lassiﬁcation Mild-Moderate Severe
12 2
a - -
b 23 9
- 1
The 2b severe ESAVIs consisted of eight YFV-AND and one
FV-VD, whereas the two severe type 1 ESAVIs consisted of
ne urinary sepsis and a sepsis-like case without ﬁnal diag-
osis. The type 3 ESAVI was an ADEM.
Neither reactions nor programmatic errors were
eported.
YFV-VD rate was 0.5/1.000.000 doses; YFV-AND
.4/1.000.000 doses No particular vaccine lot was
elated to ESAVIs. Global incidence of ESAVIs coincides
ith the heretofore published data. However, some of
he authors knew of more clinically compatible YFV-AND
nd VD non-studied cases, and there is strong suspicion of
nderreporting.
Conclusion: An accurate surveillance system and a refer-
nce laboratory are fundamental for ESAVIs study. Detailed
eports for valid conclusions and opportune actions, plus
multidisciplinary work for rigorous analysis is needed.
carefully managed risk-beneﬁt balance when prescribing
FV alongside with updated epidemiological information for
ccurate guidance is critical.
oi:10.1016/j.ijid.2010.02.629
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BIRMEX, D.F., Mexico
Background: BCG vaccine is the only preventive measure
gainst tuberculosis. At least two genomes from BCG, Pas-
eur and Japan, have been described. Evolutionary schemes
stablish by DU2 and other markers situated BCG Japan and
asteur into group I and IV from genealogy of BCG vac-
ines, respectively, classiﬁed as early and late strains. Some
CG such as Mexico 1931 is not included in any comparative
tudies based on phenotypic, genotyping, immune response
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nd drug resistance. Our aim was to characterize by full
equence BCG Mexico 1931 for using in the new develop
accine.
Methods: The sequence of BCG Mexico 1931 was per-
ormed with 2X pyrosequencing method. BCG Mexico 1931
enetic proﬁle was performed by multiplex PCR and PFGE.
he multiplex PCR was performed to detect RD and DU
egions in strains. The reference BCG strains used in this
tudy were Pasteur 1173P2, Phipps, Tice and Danish 1331.
Results: The circular chromosome at 99.8% coverage of
CG Mexico 1931 was 4 350 386-bp, its analyses conﬁrm the
D1, RD2, nRD18 absence and the presence of duplication
U2 group IV described by multiplex PCR. The comparison of
CG Pasteur1173P2 genome sequence with BCG Mexico 1931
howed differences between strains, including the presence
f RD14, SNPs and the absence of DU1. In addition, three
ew RD regions of 53, 655 and 2847 bp were uncovered. The
omparison of proﬁles obtained by PCR multiplex showed
hat BCG Mexico 1931 proﬁle was identical to BCG Phipps
nd Tice, with the lost of RD1, RD2, nRD18 and presence of
U2 group IV. PFGE was performed with AsnI/DraI enzymes,
he analyses detected 18/12 fragments in BCG Danish 1331
nd Mexico 1931, 17/12 in Pasteur 1173P2, 15/10 in Phipps
nd 14/10 in Tice, respectively. Interesting, the restriction
attern with AsnI showed the presence of 220 kb fragment
nly in BCG Mexico, Tice and Phipps.
Conclusion: The BCG Mexico 1931 showed a close rela-
ion with BCG Phipps and Tice, strains situated into group IV
rom genealogy of BCG vaccines. However, in diverse studies
hese strains shown differences on the induction of immune
esponse.
oi:10.1016/j.ijid.2010.02.630
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neumococcal vaccination - is hyporesponsiveness a prob-
em?
. Lode
RCMS, Berlin, Germany
Background: Several studues in the past have
emostrated that the pneumococcal polysaccharide
accine (PPV 23) will induce hyporesponsiveness in vacci-
ated patients over a long time period. The duration of
his effect and the impactv on a second vaccination with
conjugated vaccine (PCV 13) after at least 3 years is not
nown.
Methods: To address these open questions we investi-
ated 55 persons (30 males, age between 68 and 87 years),
ho had a ﬁrst PPV 23 - vaccination 3 - 8 years before
nd received a second vaccination with PCV 13. Immedi-
tely before and 4 - 6 weeks after PCV 13 vaccination
lood specimen were taken and antibodies to 13 individ-
al poysaccharides (1,3,4,5,6A,6B,7F,9 V,14,18,19A,19F,25F)
ere determined by a validated enzyme-linked immunosor-
ent assay.
Results: 3 - 8 years after PPV 23 vaccination antibody
oncentrations were low but in 11 out of 13 serotypes still
bove 1,0 !g/ml (the assumed protection level for adults);
nly serotypes 3 and 23F had mean concentrations (+/- SD)
f 0,66+/- 0,38 !g/ml and 0,57+/- 0.39 !g/ml. 4 - 6 weeks
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fter vaccination with PCV 13 all serotypes showed an signif-
cant increase in antibody concentrations; however, a great
esponse variability between the different serotypes was
easured with small antibody increases in serotype 3 and
igh concentrations in serotypes 4, 5,7F,19A and 19F.The
olerance of vaccination with PCV 13 was excellent.
Conclusion: The results of this study demonstrate that
ﬁrst PPV 23 vaccination has only limited impact on a
econd vaccination with a new conjugated pneumococcal
accine(PVP13) 3 - 8 years later. Hyporesponsiveness was
ot a major problem in this study. However, these results
ave to be conﬁrmed in a study with a greater number of
lderly patients.
oi:10.1016/j.ijid.2010.02.631
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ntravenous immunoglobulin manufactured from selected
hinese donors protects mice from lethal Enterovirus 71
nfection
. Cao, J. Han, E. Qin, C. Qin ∗
Beijing Institute of Microbiology and Epidemiology, Beijing,
hina
Background: Enterovirus 71 (EV71) has emerged as a
igniﬁcant cause of acute encephalitis and paralysis in
hina, resulting in hundreds of deaths in young children
ince 2006. Passive transfer of intravenous immunoglobu-
in (IVIG) from Chinese donors has been associated with
educed mortality in children with severe EV71 infec-
ions. The anti-EV71 neutralization antibodies in Chinese
VIG products may contribute to the protection from EV71
nfection.
Methods: A modiﬁed high-throughput microneutraliza-
ion assay was performed to screen for plasma units
ontaining high titer (>100) anti-EV71 antibodies from Chi-
ese plasma donors. Positive units were then pooled and
rocessed into pharmaceutical grade EV71-speciﬁc IVIG
EV71-IVIG). Different doses (0.1 to 5mg) of EV71-IVIG and
ommercial IVIG were administered following lethal EV71
nfection in sucking mice, respectively, according to the spe-
iﬁc experimental protocol. Mice were monitored daily for
ody weight and mortality.
Results: About 10% of the plasma units from Chinese
lasma donors were selected to produce EV71-IVIG. In vitro
eutralization assays showed that the anti-EV71 antibod-
es titer (>1024) in EV71-IVIG preparations was 10-fold
igher than that in commercial IVIG preparations. Full
rotection was archived when the infected mice were
reated with EV71-IVIG, while similar treatments using com-
ercial IVIG had no protective effect. Recovery of the
nfected mice was dependent on the dose and time of IVIG
dministration.Conclusion: These results demonstrated that IVIG with
igher titer (>1024) neutralization antibodies conferred pro-
ection against lethal EV71 challenge in an animal model.
his ﬁnding also suggested that blood from selected donors
n EV71 endemic regions can improve the potency of IVIG and
